Richard A. Mortimer

Education

Ph.D., economics, University of California, Berkeley; B.A., economics, the Johns Hopkins University

Summary of Experience

Dr. Mortimer specializes in health economics, industrial organization, microeconomic theory, and econometrics. He has provided economic analyses in numerous antitrust matters involving questions of market power, pricing, and market exclusion and foreclosure in a variety of industries, with a focus on healthcare. He also has provided analyses and expert testimony on behalf of clients in the healthcare industry on litigation and government investigations involving allegations of improper promotion and kickback payments. Dr. Mortimer's experience includes leading analyses of large data sets to assess questions of market definition, class certification, liability, and damages. In addition to work in litigation, Dr. Mortimer also has undertaken research in the area of healthcare policy, and he has authored several public policy studies related to pharmaceutical and general healthcare legislation. His research has been published in leading peer-reviewed journals, including Health Affairs, Nature Reviews Drug Discovery, The Journal of Industrial Economics, and the Journal of Medical Economics.

Selected Cases

• Authorized Generics, Competition, and Consumer Prices
• Pharmaceutical Off-Label Promotion & Kickbacks Settlements

Selected Publishing

• Cardiac arrhythmia detection outcomes among patients monitored with the Zio patch system: a systematic literature review

  Current Medical Research and Opinion, 2019
  2019

  Yenikomshian M, Jarvis J, Patton C, Yee C, Mortimer R, Birnbaum H, Topash M

  Health Care
• The Economics of Biosimilar Drugs and New Considerations in Intellectual Property and Antitrust Litigation

  Public Domain: The Newsletter of the ABA Section of Antitrust Law’s Intellectual Property Committee, July 2018
  2018

  Mortimer R, Ellman B

  Antitrust & Competition, Health Care, Intellectual Property
• The Rise of Biosimilars and the Future of Healthcare Intellectual Property

  IAM, November/December 2018
  2018

  Mortimer R, Ellman B

  Health Care, Intellectual Property
• Can The Life Sciences Industry Bank On Biosimilars?

  Law360, April 13, 2016
  2016

  Greenberg P, Sisitsky T, Mortimer R

  Health Care
• Correlation Or Cause: Brand-Name Drug Prescription Rates

  Law360, March 23, 2016
  2016

  Greenberg P, Sisitsky T, Mortimer R

  Health Care
• The Potential For Litigation In New Era Of Biosimilars

  Law360, September 20, 2016
  2016

  Frois C, Mortimer R, White A

  Antitrust & Competition, Health Care, Intellectual Property
• Updated trends in US brand-name and generic drug competition

  Journal of Medical Economics, 2016 04: 1-9. e-pub ahead of print 2016/04/12
  2016

  Grabowski H, Long G, Mortimer R, Boyo A.

  Health Care
• Recent Trends in Brand Name and Generic Drug Competition

  Journal of Medical Economics, March 2014
  2014

  Grabowski H, Long G, Mortimer R

  Health Care, Strategy, Policy & Analytics
• Recent Average Price Trends for Implantable Medical Devices, 2007-2011

  White Paper
  2013

  Long G, Mortimer R, Sanzenbacher G

  Health Care, Strategy, Policy & Analytics
• Data Exclusivity for Biologics

  Nature Reviews Drug Discovery 10, 15-16 (January 2011) - doi:10.1038/nrd3277
  2011

  Long G, Mortimer R, Grabowski H

  Health Care, Intellectual Property, Strategy, Policy & Analytics
• Evolving Brand-Name and Generic Drug Competition May Warrant a Revision of the Hatch-Waxman Act

  Health Affairs, 2011, 30(11), 2157-2166
  2011

  Grabowski HG, Kyle M, Mortimer R, Long G, Kirson N

  Health Care, Intellectual Property, Strategy, Policy & Analytics
• Implementation of the Biosimilar Pathway: Economic and Policy Issues

  Seton Hall Law Review, Book 2, 41:2
  2011

  Grabowski HG, Long G, Mortimer R

  Health Care, Intellectual Property, Strategy, Policy & Analytics
• Data Exclusivity Periods and Next Generation Improvements to Innovator Biologics: Key Issues

  Duke University Department of Economics Working Paper, No. 2009-05
  2009

  Grabowski H, Cockburn I,  Long G,  Mortimer R

  Health Care
• Data Exclusivity Periods for Biologics: Updating Prior Analyses and Responding to Critiques

  Duke University Department of Economics Working Paper, No. 2008-10
  2008

  Grabowski H, Long G, Mortimer R

  Health Care
• The Effect on Federal Spending of Legislation Creating a Regulatory Framework for Follow-on Biologics: Key Issues and Assumptions

  White Paper
  2007

  Grabowski H, Cockburn I, Long G, Mortimer R, Johnson S

  Health Care
• Authorized Generic Drugs, Price Competition, And Consumers’ Welfare

  Health Affairs - 26, no. 3 (2007): 790-799
  2007

  Berndt E, Parece A, Tuttle E, Mortimer R, Bhattacharjya A

  Health Care, Strategy, Policy & Analytics
• Do Authorized Generic Drugs Deter Paragraph IV Certifications? Recent Evidence

  Working Paper: April 17, 2007
  2007

  Berndt E, Mortimer R, Parece A

  Health Care, Strategy, Policy & Analytics

News

• August 13, 2018

  Analysis Group Team Publishes Article on New Economic Considerations for Biosimilar Drug Intellectual Property and Antitrust Litigation

  Antitrust & Competition, Health Care, Intellectual Property